Novan, Inc. (NOVN): Price and Financial Metrics

Novan, Inc. (NOVN)

Today's Latest Price: $1.28 USD

0.09 (7.56%)

Updated Jan 28 10:35am

Add NOVN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 241 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NOVN Stock Summary

  • The ratio of debt to operating expenses for Novan Inc is higher than it is for about just 6.24% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -5.54 for Novan Inc; that's greater than it is for only 2.83% of US stocks.
  • With a year-over-year growth in debt of -85.07%, Novan Inc's debt growth rate surpasses merely 2.51% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Novan Inc are AKER, SINT, MNDO, AUMN, and MTP.
  • Visit NOVN's SEC page to see the company's official filings. To visit the company's web site, go to

NOVN Stock Price Chart Interactive Chart >

Price chart for NOVN

NOVN Price/Volume Stats

Current price $1.28 52-week high $1.57
Prev. close $1.19 52-week low $0.22
Day low $1.14 Volume 4,920,812
Day high $1.31 Avg. volume 29,098,479
50-day MA $0.80 Dividend yield N/A
200-day MA $0.58 Market Cap 181.14M

Novan, Inc. (NOVN) Company Bio

Novan, Inc. focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company was founded in 2006 and is based in Durham, North Carolina.

NOVN Latest News Stream

Event/Time News Detail
Loading, please wait...

NOVN Latest Social Stream

Loading social stream, please wait...

View Full NOVN Social Stream

Latest NOVN News From Around the Web

Below are the latest news stories about Novan Inc that investors may wish to consider to help them evaluate NOVN as an investment opportunity.

Novan: Despite Phase 3 Failures, FDA Is Allowing Another Effort

Nobody has written a single article on Novan, Inc. (NOVN) on Seeking Alpha in the last five years. That’s possibly because their lead asset SB206 failed two phase 3 clinical trials targeting molluscum contagiosum. Both the B-SIMPLE-1 and 2 trials failed to achieve the primary endpoint of complete clearance of...

Avisol Capital Partners on Seeking Alpha | January 24, 2021

Novan Provides Enrollment Update and Announces New Corporate Headquarters

– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to support various cGMP activities, including research and development and small-scale manufacturing capabilities – MORRISVILLE, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today provided an update that enrollment for its B-SIMPLE4 pivotal Phase 3 study evaluating SB206, a topical antiviral gel for the treatment of molluscum contagiosum (“molluscum”), has reached 90% of the approximately 850 subjects targeted for enrollment in the study. In addition, the Company has entered into a lease agreement for approximately 15,000 square feet at a new locat...

Yahoo | January 19, 2021

SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Novan, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Novan, Inc. (NASDAQ: NOVN).

Yahoo | January 13, 2021

Novan to Present at the H.C. Wainwright BioConnect 2021 Virtual Conference

MORRISVILLE, N.C., Jan. 08, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford,…

GlobeNewswire | January 8, 2021

Novan Engages Catalent to Develop Intranasal Formulation of Berdazimer Sodium for COVID-19 Program

– Catalent has a proven track record of accelerating molecules from early development through commercial manufacturing – – Company targets initiating preclinical Investigational New Drug (IND) enabling studies in Q1 2021 – MORRISVILLE, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a Master Services Agreement (MSA) with Catalent, which will include support of chemistry, manufacturing and control (CMC) activities and development of an intranasal formulation of berdazimer sodium for use in the Company’s coronavirus (COVID-19) program. Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and c...

Yahoo | December 21, 2020

Read More 'NOVN' Stories Here

NOVN Price Returns

1-mo 83.07%
3-mo 178.26%
6-mo 92.31%
1-year 102.12%
3-year -64.15%
5-year N/A
YTD 57.44%
2020 -74.27%
2019 280.72%
2018 -80.33%
2017 -84.38%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8235 seconds.